Sonidegib CAS# 956697-53-3 雷特格韦
Sonidegib, also known as, erismodegib, LDE225, NVP-LDE225, is an orally bioavailable small-molecule Smoothened (Smo) antagonist with potential antineoplastic activity. Erismodegib selectively binds to the Hedgehog (Hh)-ligand cell surface receptor Smo, which may result in the suppression of the Hh signaling pathway and, so, the inhibition of tumor cells in which this pathway is abnormally activated. It was approved by the FDA for treating basal cell carcinoma in July 2015.
📌 参考资料/链接：
Reference: Wang, Deyin; Xu, Xin; Qi, Yuxin; Wang, Baolin; Zhang, Wei; Zhao, Yinlong. Preparation of Sonidegib and intermediate thereof. CN 109293649. (Xinfa Pharmaceutical Co., Ltd., Peop. Rep. China)
Reference: Wang, Deyin; Xu, Xin; Qi, Yuxin; Wang, Baolin; Zhang, Wei; Zhao, Yinlong. Preparation of Sonidegib and intermediate thereof. CN 109293649. (Xinfa Pharmaceutical Co., Ltd., Peop. Rep. China)
📄 详细内容
CAS No. 956697-53-3 雷特格韦Sonidegib synthetic routes
Wang, Deyin; Xu, Xin; Qi, Yuxin; Wang, Baolin; Zhang, Wei; Zhao, Yinlong. Preparation of Sonidegib and intermediate thereof. CN 109293649. (Xinfa Pharmaceutical Co., Ltd., Peop. Rep. China)
产品链接: CAS No. 956697-53-3 ››
Wang, Deyin; Xu, Xin; Qi, Yuxin; Wang, Baolin; Zhang, Wei; Zhao, Yinlong. Preparation of Sonidegib and intermediate thereof. CN 109293649. (Xinfa Pharmaceutical Co., Ltd., Peop. Rep. China)
产品链接: CAS No. 956697-53-3 ››